Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.590
-0.050 (-1.37%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
57
Market Cap
232.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Century Therapeutics | 109.16M |
| Bicycle Therapeutics | 61.21M |
| Q32 Bio | 53.74M |
| AC Immune | 21.67M |
| Lineage Cell Therapeutics | 13.08M |
| Palisade Bio | 500.00K |
| SAB Biotherapeutics | 114.70K |
IMRX News
- 16 days ago - Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 17 days ago - 3 ‘Strong Buy’ Stocks Under $10 to Watch in October for 100%+ Upside - TipRanks
- 20 days ago - Immuneering presents new data at 2026 AACR on atebimetinib - TheFly
- 20 days ago - Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer - GlobeNewsWire
- 24 days ago - Immuneering to Present at the ESMO Congress 2026 - GlobeNewsWire
- 4 weeks ago - Immuneering Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Immuneering Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival - GlobeNewsWire